Tivopath tivozanib regulatory update

Aveo disclosed in an SEC filing that partner Astellas said it no longer plans to submit an MAA to EMA for tivozanib to treat advanced renal cell carcinoma (RCC). According to Aveo, Astellas does not intend to fund future trials in RCC. Aveo said it is also evaluating the path forward for the indication. Tivozanib is in Phase II testing for breast and colorectal cancer. Astellas could not be reached for comment. ...